Reducing Hereditary Cancer Act of 2023

12/15/2023, 4:06 PM

Reducing Hereditary Cancer Act of 2023

This bill provides for Medicare coverage of germline mutation testing for individuals with a personal or family history of a hereditary cancer gene mutation or suspected history of hereditary cancer, as well as for associated coverage of risk-reducing surgeries and screenings.

Congress
118

Number
S - 765

Introduced on
2023-03-09

# Amendments
0

Sponsors
+5

Cosponsors
+5

Variations and Revisions

3/9/2023

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Reducing Hereditary Cancer Act of 2023

This bill provides for Medicare coverage of germline mutation testing for individuals with a personal or family history of a hereditary cancer gene mutation or suspected history of hereditary cancer, as well as for associated coverage of risk-reducing surgeries and screenings.

Alternative Names
Official Title as IntroducedA bill to amend title XVIII of the Social Security Act to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer.

Policy Areas
Health

Potential Impact
Cancer
Genetics
Health care coverage and access
Health promotion and preventive care
Hereditary and development disorders
Medical tests and diagnostic methods
Medicare

Comments

Recent Activity

Latest Summary4/4/2023

Reducing Hereditary Cancer Act of 2023

This bill provides for Medicare coverage of germline mutation testing for individuals with a personal or family history of a hereditary cancer gene mutation or suspected history of hered...


Latest Action3/9/2023
Read twice and referred to the Committee on Finance.